New gene therapy platform uses the brain's own transport system to target glial cells

Researchers at University of Rochester have engineered AAV vectors that target glial cells and exploit the brain's glymphatic system for gene delivery, enabling widespread therapeutic distribution while avoiding peripheral organs. The platform addresses both blood-brain barrier penetration and cellular selectivity, opening new treatment routes for progressive MS, Huntington's disease, and white matter disorders.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.